Niu, J., Milhem, M., Vanderwalde, A. M., Chmielowski, B., Beasley, G., Samson, A., … Middleton, M. R. (2022). Safety and Efficacy of RP1+Nivolumab in Patients with Non-Melanoma Skin Cancer of the Head and Neck: Results From IGNYTE Phase 1/2 Multi-Cohort Clinical Trial. In INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (Vol. 112, pp. E8–E9).

Niu, J., M. Milhem, A. M. Vanderwalde, B. Chmielowski, G. Beasley, A. Samson, J. J. Sacco, et al. “Safety and Efficacy of RP1+Nivolumab in Patients with Non-Melanoma Skin Cancer of the Head and Neck: Results From IGNYTE Phase 1/2 Multi-Cohort Clinical Trial.” In INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 112:E8–9, 2022.

Niu J, Milhem M, Vanderwalde AM, Chmielowski B, Beasley G, Samson A, et al. Safety and Efficacy of RP1+Nivolumab in Patients with Non-Melanoma Skin Cancer of the Head and Neck: Results From IGNYTE Phase 1/2 Multi-Cohort Clinical Trial. In: INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2022. p. E8–9.

Niu, J., et al. “Safety and Efficacy of RP1+Nivolumab in Patients with Non-Melanoma Skin Cancer of the Head and Neck: Results From IGNYTE Phase 1/2 Multi-Cohort Clinical Trial.” INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, vol. 112, no. 5, 2022, pp. E8–9.

Niu J, Milhem M, Vanderwalde AM, Chmielowski B, Beasley G, Samson A, Sacco JJ, Bowles T, Jew T, He S, Raza S, Harrington K, Middleton MR. Safety and Efficacy of RP1+Nivolumab in Patients with Non-Melanoma Skin Cancer of the Head and Neck: Results From IGNYTE Phase 1/2 Multi-Cohort Clinical Trial. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2022. p. E8–E9.